Immune-checkpoint inhibitors (ICIs) have shown to improve survival in the first-and second-
line settings of recurrent/metastatic squamous cell carcinoma of the head and neck …

Head and neck squamous cell carcinoma (HNSCC) constitutes a significant global cancer
burden, given its high prevalence and associated mortality. Despite substantial progress in …

Purpose The first aim of the trial is to study feasibility of combined programmed death protein
ligand 1/cytotoxic T-lymphocyte-associated protein 4 inhibition concomitant to radiotherapy …

Human papillomavirus (HPV)–driven oropharyngeal carcinoma (OPSCC) is distinct from
tobacco-or alcohol-associated OPSCC and has a unique immune landscape. Studies have …

Objectives To assess the predictive value of multiparametric MRI for treatment response
evaluation of induction chemo-immunotherapy in locally advanced head and neck …

While the treatment of squamous cell carcinoma of the head and neck (HNSCC) with
radiotherapy (RT) is complemented more and more by immunotherapy in clinical trials, little …

Despite recent advances in treatment, the prognosis of oral cancer remains poor, and
prevention of recurrence and metastasis is critical. Olaparib is a PARP1 inhibitor that blocks …

Immunotherapy has become a mainstay treatment for HNSCC, with the FDA (Food and Drug
Administration) approval of the anti-PD-1 immune checkpoint inhibitors (ICIs) nivolumab and …

Immunotherapy has become one of the most promising approaches in tumor therapy, and
there are numerous associated clinical trials in China. As an immunosuppressive tumor …

Novel chemo-immunotherapy (chemo-IO) combinations should be evaluated, which may be
suitable for cisplatin-unfit or fluoropyrimide-ineligible patients with recurrent or metastatic …